ALXN

Alexion Pharmaceuticals Inc

A biopharmaceutical company focused on rare, life-threatening diseases, Alexion makes medicines like Soliris and Ultomiris that treat ultra-rare blood disorders such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. It was founded in 1992 by Yale professor Leonard Bell in New Haven, Connecticut, and was acquired by AstraZeneca in 2021. The name reportedly echoes Alexion, an ancient Greek physician and friend of Cicero, with a root meaning "to ward off or defend."

No 8-K or 6-K filings recorded.